Gelardi M, Barbara F, Covelli I, Damiani M A, Plantone F, Notarnicola A, Moretti B, Quaranta N, Ciprandi G
1Otolaryngology Unit, Department of Basic Medical Science, Neuroscience and Sensory Organs, University of Bari Aldo Moro, Bari, Italy.
2Orthopaedic, Trauma and Spine Unit, Department of Basic Medical Sciences, Neuroscience and Sense Organs, School of Medicine, University of Bari Aldo Moro, AOU Consorziale Policlinico, Bari, Italy.
Indian J Otolaryngol Head Neck Surg. 2019 Nov;71(Suppl 3):2050-2056. doi: 10.1007/s12070-018-1466-5. Epub 2018 Aug 1.
Chronic rhinosinusitis associated with nasal polyposis (RSCwNP) affects 4% of the general population. As chronic condition, it requires chronic pharmacological treatment, whereas the surgical approach becomes necessary in obstructive and/or complicated cases. Intranasal and systemic corticosteroids (CS) represent the "Gold Standard" treatment for RSCwNP. The present study aimed to evaluate the side effects of prednisone in a group of patients with RSCwNP treated with long-term CS. In particular, attention was focused on bone disorders (osteopenia and osteoporosis) and prospective fracture risk increase. Forty patients (26 females, mean age 55.70 ± 14.03 years) affected by RSCwNP have been enrolled. Control group included 40 healthy subjects (17 females, mean age 56.37 ± 13.03 years). Nasal endoscopy, skin prick tests, nasal cytology, and bone densitometry were evaluated in all subjects. The likelihood of impaired bone metabolism (osteopenia or osteoporosis) was superimposable in both groups. Within RSCwNP group, no parameter was statistically significant in predicting a metabolism alteration.
伴有鼻息肉的慢性鼻窦炎(RSCwNP)影响4%的普通人群。作为一种慢性疾病,它需要长期药物治疗,而在阻塞性和/或复杂性病例中手术治疗则很有必要。鼻内和全身用皮质类固醇(CS)是RSCwNP的“金标准”治疗方法。本研究旨在评估长期使用CS治疗的RSCwNP患者中泼尼松的副作用。特别关注的是骨骼疾病(骨质减少和骨质疏松)以及预期骨折风险增加。已招募了40例受RSCwNP影响的患者(26名女性,平均年龄55.70±14.03岁)。对照组包括40名健康受试者(17名女性,平均年龄56.37±13.03岁)。对所有受试者进行了鼻内镜检查、皮肤点刺试验、鼻细胞学检查和骨密度测定。两组骨代谢受损(骨质减少或骨质疏松)的可能性相当。在RSCwNP组中,没有参数在预测代谢改变方面具有统计学意义。